This 2016 update on Acute Lymphocytic Leukemia (ALL) from Noelle Frey, MD, features a review of treatment approaches for ALL patients in the unique adolescent/young adult population, among other findings. Reviewing clinical trials that suggest a correlation between improved outcomes in this population when exposed to an intensity of treatment typical of pediatric ALL patients, Dr Frey notes the rapid decline in tolerability beyond age 20. For adult patients in relapse, Dr. Frey reports on studies that found durable remission and cure dependent on the capacity to bridge patients to an allogeneic transplant, and speaks to the value of detecting minimal residual disease as a correlate to prognosis throughout the course of disease.
Related Links
Published
December 7, 2016
Created by
BROADCASTMED